Extracorporeal membrane oxygenation (ECMO), as an important advanced continuous extracorporeal life support technology, is primarily used clinically for the support of cardiac and/or respiratory insufficiency. It has now become a key technology for treating uncontrollable severe heart failure and respiratory failure. With increasing clinical demand for patients, the continuous advancement of ECMO localization, the release of relevant supportive national policies, and capital support, the Chinese ECMO industry is expected to achieve rapid development in the future. At the same time, the application fields and departments of ECMO continue to expand, covering multiple dimensions of ECMO use scenarios. The potential market for ECMO in the future will include mature, rapidly growing, and high-potential application markets, with a market scale showing potential for rapid growth.
Frost & Sullivan (Frost & Sullivan, abbreviated as 'Frost & Sullivan') released the 'ECMO Industry Status quo and Development Trends Report' on June 1, 2023. This report provides an in-depth analysis of the ECMO industry overview, application scenarios, current status of the global and Chinese ECMO markets, and industry pain points. It aims to uncover the driving factors behind market development and reflect the overall development trends of the ECMO industry.
